
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" href="../style.css">
    <title>Document</title>
</head>
<body>

<span class="table_title">False Negatives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>1</th>
      <td></td>
      <td>females</td>
      <td>The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.</td>
    </tr>
    <tr>
      <th>0</th>
      <td>women</td>
      <td>women<br>female</td>
      <td>Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone–related cancers; 4) women with uncontrolled hypertension (160/100 mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1 yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk; 12) women who were administered female hormone formulations within 6 mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10 h) within 3 mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1 mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.</td>
    </tr>
  </tbody>
</table>
<span class="table_title">False Positives</span>

<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th>generated</th>
      <th>gold</th>
      <th>text</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>11</th>
      <td>women</td>
      <td></td>
      <td>Polycystic ovary syndrome (PCOS) patients’ flow diagram.</td>
    </tr>
    <tr>
      <th>3</th>
      <td>male</td>
      <td></td>
      <td>2).</td>
    </tr>
    <tr>
      <th>9</th>
      <td>women</td>
      <td></td>
      <td>This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.</td>
    </tr>
    <tr>
      <th>34</th>
      <td>women</td>
      <td></td>
      <td>Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).</td>
    </tr>
    <tr>
      <th>19</th>
      <td>women</td>
      <td></td>
      <td>If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.</td>
    </tr>
    <tr>
      <th>10</th>
      <td>men</td>
      <td></td>
      <td>However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.</td>
    </tr>
    <tr>
      <th>13</th>
      <td>she</td>
      <td></td>
      <td>At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.</td>
    </tr>
    <tr>
      <th>1</th>
      <td>women</td>
      <td></td>
      <td>The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].</td>
    </tr>
    <tr>
      <th>17</th>
      <td>rats<br>children</td>
      <td></td>
      <td>As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].</td>
    </tr>
    <tr>
      <th>22</th>
      <td>women</td>
      <td></td>
      <td>Approximately 70–80% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.</td>
    </tr>
    <tr>
      <th>4</th>
      <td>male</td>
      <td></td>
      <td>Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.</td>
    </tr>
    <tr>
      <th>7</th>
      <td>unknown</td>
      <td></td>
      <td>(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.</td>
    </tr>
    <tr>
      <th>35</th>
      <td>male</td>
      <td></td>
      <td>et Zucc.)</td>
    </tr>
    <tr>
      <th>6</th>
      <td>male</td>
      <td></td>
      <td>Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin  tmax (h)\t1.4 (1.1–1.6)\t1.9 (1.1–2.7)\t1.3 (1.1–1.6)\tNA\tNA  Cmax (μg mL−1)\t1.8 (1.7–1.9)\t1.7 (1.5–2.0)\t1.9 (1.5–2.2)\t0.94 (0.67–1.29)\t1.06 (0.77–1.47)  t1/2 (h)\t38.6 (35.7–41.5)\t34.9 (31.0–38.8)\t41.2 (35.1–47.3)\t0.94 (0.79–1.12)\t0.99 (0.83–1.18)  AUC (μg mL−1 h)\t60.3 (54.5–66.1)\t63.0 (57.3–68.8)\t65.5 (55.3–75.6)\t1.04 (0.94–1.67)\t1.06 (0.95–1.19)  CL/F (mL h−1)\t213 (193–232)\t204 (183–224)\t202 (175–229)\t0.89 (0.80–0.99)\t1.05 (0.94–1.17)  Fraction unbound (fu)\t0.010 (0.007–0.013)\t0.010 (0.007–0.014)\t0.011 (0.008–0.014)\t1.00 (0.75–1.25)\t1.12 (0.39–1.84)  \t \t \t \t \t  R-warfarin  tmax (h)\t1.4 (1.1–1.6)\t1.9 (1.1–2.7)\t1.8 (0.7–2.9)\tNA\tNA  Cmax (μg mL−1)\t1.8 (1.7–2.0)\t1.7 (1.5–1.9)\t1.9 (1.5–2.2)\t0.90 (0.67–1.21)\t1.02 (0.8–1.4)  t1/2 (h)\t55.6 (46.2–65.0)\t47.7 (41.5–53.9)\t52.6 (47.4–57.9)\t0.93 (0.80–1.08)\t0.98 (0.84–1.14)  AUC (μg mL−1 h)\t108.7 (90.0–127.3)\t105.8 (91.7–119.9)\t105.0 (96.3–113.7)\t1.0 (0.9–1.1)\t0.99 (0.87–1.13)  CL/F (mL h−1)\t123 (106–140)\t124 (109–139)\t121 (112–131)\t0.87 (0.75–0.99)\t0.96 (0.84–1.11)  Fraction unbound (fu)\t0.006 (0.004–0.007)\t0.005 (0.004–0.007)\t0.006 (0.004–0.007)\t0.95 (0.72–1.18)\t1.04 (0.80–1.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration–time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.</td>
    </tr>
    <tr>
      <th>0</th>
      <td>female</td>
      <td></td>
      <td>Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.</td>
    </tr>
    <tr>
      <th>31</th>
      <td>women</td>
      <td></td>
      <td>Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.</td>
    </tr>
    <tr>
      <th>8</th>
      <td>female</td>
      <td></td>
      <td>O caso ocorreu em uma paciente previamente hígida de 35 anos de idade que foi submetida a investigação exaustiva após a exclusão de outras possíveis causas.</td>
    </tr>
    <tr>
      <th>12</th>
      <td>not specified</td>
      <td></td>
      <td>does not affect CYP2C19 activity when administered over an 8-day period.</td>
    </tr>
    <tr>
      <th>29</th>
      <td>male</td>
      <td></td>
      <td>Go to: 2.</td>
    </tr>
    <tr>
      <th>25</th>
      <td>women<br>men</td>
      <td></td>
      <td>3a and b).</td>
    </tr>
    <tr>
      <th>33</th>
      <td>male</td>
      <td></td>
      <td>At 30 min following the 8PM dose on Day 5, the rats were anesthetized and about 10 mL of blood were collected from rats’ inferior vena for determination of antiviral activity.</td>
    </tr>
    <tr>
      <th>2</th>
      <td>male</td>
      <td></td>
      <td>KY[2017]073).</td>
    </tr>
    <tr>
      <th>32</th>
      <td>women</td>
      <td></td>
      <td>2020; 81:XXX–XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.</td>
    </tr>
    <tr>
      <th>21</th>
      <td>women</td>
      <td></td>
      <td>Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.</td>
    </tr>
    <tr>
      <th>20</th>
      <td>male</td>
      <td></td>
      <td>a.</td>
    </tr>
    <tr>
      <th>30</th>
      <td>women</td>
      <td></td>
      <td>The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37 months (range 4–113) from completion of chemotherapy.</td>
    </tr>
    <tr>
      <th>14</th>
      <td>male<br>female</td>
      <td></td>
      <td>Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.</td>
    </tr>
    <tr>
      <th>23</th>
      <td>mixed gender</td>
      <td></td>
      <td>(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), β-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).</td>
    </tr>
    <tr>
      <th>24</th>
      <td>rats</td>
      <td></td>
      <td>In selectivity testing, six rats plasma was used.</td>
    </tr>
    <tr>
      <th>5</th>
      <td>rats</td>
      <td></td>
      <td>used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).</td>
    </tr>
    <tr>
      <th>16</th>
      <td>human</td>
      <td></td>
      <td>Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63–65].</td>
    </tr>
    <tr>
      <th>27</th>
      <td>male<br>female</td>
      <td></td>
      <td>1).</td>
    </tr>
  </tbody>
</table>

</body>
</html>
